nogrЭкспериментальная и клиническая гастроэнтерологияExperimental and Clinical Gastroenterology1682-8658«Global Media Technologies»10.31146/1682-8658-ecg-235-3-148-151nogr-3141Research ArticleМЕТАБОЛИЧЕСКИЙ СИНДРОМMETABOLIC SYNDROMEКатестатин как потенциальный маркер метаболического синдромаCatestatin as a potential diagnostic marker of metabolic syndromeКузнецоваД. К.KuznetsovaD. K.d.k.kuznetsova@samsmu.ruhttps://orcid.org/0000-0003-1881-024XГубареваИ. В.GubarevaI. V.noemail@neicon.ruhttps://orcid.org/0000-0002-0162-1349ПашенцеваА. В.PashentsevaA. V.noemail@neicon.ruФедеральное государственное бюджетное образовательное учреждение высшего образования «Самарский государственный медицинский университет» Министерства здравоохранения Российской ФедерацииРоссияSamara State Medical UniversityRussian Federation20252910202503148151Copyright © Кузнецова Д.К., Губарева И.В., Пашенцева А.В., 20252025Кузнецова Д.К., Губарева И.В., Пашенцева А.В.Kuznetsova D.K., Gubareva I.V., Pashentseva A.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.nogr.org/jour/article/view/3141

Цель исследования: оценить возможность использования катестатина как биомаркера для диагностики метаболического синдрома. Материалы и методы: в основе исследования лежал поиск публикаций преимущественно за последние 5 лет по базам данных PubMed и Google Scholar по ключевым словам «катестатин», «метаболический синдром», «инсулинорезистентность», «дислипидемия». Результаты: катестатин - это многофункциональный пептид, который может стать перспективным инструментом для диагностики метаболического синдрома. Он воздействует на адренергическую систему, уменьшая чувствительность к катехоламинам и вызывая расширение сосудов. Кроме того, катестатин влияет на обмен веществ, снижая уровни триглицеридов и лептина. Он также регулирует инсулинорезистентность и обладает противовоспалительным эффектом. Заключение: катестатин может быть полезным инструментом для диагностики и лечения метаболического синдрома. Однако для полного понимания его роли и определения оптимальных методов применения необходимы дальнейшие исследования.

Aim of the study: to evaluate the possibility of using catestatin as a biomarker for the diagnosis of metabolic syndrome. Materials and methods: the study was based on a search for publications mainly over the past 5 years in the PubMed and Google Scholar databases for the keywords “catestatin”, “metabolic syndrome”, “insulin resistance”, “dyslipidemia”. Results: catestatin is a multifunctional peptide that can become a promising tool for the diagnosis of metabolic syndrome. It affects the adrenergic system, reducing sensitivity to catecholamines and causing vasodilation. In addition, catestatin affects the metabolism, reducing the levels of triglycerides and leptin. It also regulates insulin resistance and has an anti-inflammatory effect. Conclusion: catestatin may be a useful tool for the diagnosis and treatment of metabolic syndrome. However, further research is needed to fully understand its role and determine best practices.

катестатинметаболический синдроможирениевоспалениедислипидемияcatestatinmetabolic syndromeobesityinflammationdyslipidemiaReferencesBourebaba Y., Mularczyk M., Marycz K., Bourebaba L. Catestatin peptide of chromogranin A as a potential new target for several risk factors management in the course of metabolic syndrome. Biomed Pharmacother. 2021 Feb;134:111113. doi: 10.1016/j.biopha.2020.111113.Bourebaba Y., Mularczyk M., Marycz K., Bourebaba L. Catestatin peptide of chromogranin A as a potential new target for several risk factors management in the course of metabolic syndrome. Biomed Pharmacother. 2021 Feb;134:111113. doi: 10.1016/j.biopha.2020.111113.Zalewska E., Kmieć P., Sworczak K. Role of Catestatin in the Cardiovascular System and Metabolic Disorders. Front Cardiovasc Med. 2022;9:909480. Published 2022 May 19. doi: 10.3389/fcvm.2022.909480.Zalewska E., Kmieć P., Sworczak K. Role of Catestatin in the Cardiovascular System and Metabolic Disorders. Front Cardiovasc Med. 2022;9:909480. Published 2022 May 19. doi: 10.3389/fcvm.2022.909480.Watanabe T. The Emerging Roles of Chromogranins and Derived Polypeptides in Atherosclerosis, Diabetes, and Coronary Heart Disease.Int J Mol Sci. 2021 Jun 6;22(11):6118. doi: 10.3390/ijms22116118.Watanabe T. The Emerging Roles of Chromogranins and Derived Polypeptides in Atherosclerosis, Diabetes, and Coronary Heart Disease.Int J Mol Sci. 2021 Jun 6;22(11):6118. doi: 10.3390/ijms22116118.Meng L., Ye X.J., Ding W.H. et al. Plasma catecholamine release-inhibitory peptide catestatin in patients with essential hypertension. J Cardiovasc Med (Hagerstown). 2011;12(9):643-647. doi: 10.2459/JCM.0b013e328346c142.Meng L., Ye X.J., Ding W.H. et al. Plasma catecholamine release-inhibitory peptide catestatin in patients with essential hypertension. J Cardiovasc Med (Hagerstown). 2011;12(9):643-647. doi: 10.2459/JCM.0b013e328346c142.O’Connor D.T., Zhu G., Rao F. et al. Heritability and genome-wide linkage in US and australian twins identify novel genomic regions controlling chromogranin a: implications for secretion and blood pressure. Circulation. 2008 Jul 15;118(3):247-57. doi: 10.1161/CIRCULATIONAHA.107.709105.O’Connor D.T., Zhu G., Rao F. et al. Heritability and genome-wide linkage in US and australian twins identify novel genomic regions controlling chromogranin a: implications for secretion and blood pressure. Circulation. 2008 Jul 15;118(3):247-57. doi: 10.1161/CIRCULATIONAHA.107.709105.Gubareva E. Yu., Kryukov N.N., Gubareva I.V. catestatin as a novel marker of cardiovascular risk in systemic hypertension.Russian Journal of Cardiology. 2018;(4):111-116. (In Russ.) doi: 10.15829/1560-4071-2018-4-111-116.@@ Губарева Е.Ю., Крюков Н.Н., Губарева И.В. катестатин как новый маркер сердечно-сосудистого риска у больных гипертонической болезнью. Российский кардиологический журнал. 2018;(4):111-116. doi: 10.15829/1560-4071-2018-4-111-116.Gubareva E. Yu., Kryukov N.N., Gubareva I.V. catestatin as a novel marker of cardiovascular risk in systemic hypertension.Russian Journal of Cardiology. 2018;(4):111-116. (In Russ.) doi: 10.15829/1560-4071-2018-4-111-116.@@ Губарева Е.Ю., Крюков Н.Н., Губарева И.В. катестатин как новый маркер сердечно-сосудистого риска у больных гипертонической болезнью. Российский кардиологический журнал. 2018;(4):111-116. doi: 10.15829/1560-4071-2018-4-111-116.Durakoğlugil M.E., Ayaz T., Kocaman S.A. et al. The relationship of plasma catestatin concentrations with metabolic and vascular parameters in untreated hypertensive patients: Influence on high-density lipoprotein cholesterol. Anatol J Cardiol. 2015 Jul;15(7):577-85. doi: 10.5152/akd.2014.5536.Durakoğlugil M.E., Ayaz T., Kocaman S.A. et al. The relationship of plasma catestatin concentrations with metabolic and vascular parameters in untreated hypertensive patients: Influence on high-density lipoprotein cholesterol. Anatol J Cardiol. 2015 Jul;15(7):577-85. doi: 10.5152/akd.2014.5536.Mahata S.K., Corti A. Chromogranin A and its fragments in cardiovascular, immunometabolic, and cancer regulation. Ann N Y Acad Sci. 2019;1455(1):34-58. doi: 10.1111/nyas.14249.Mahata S.K., Corti A. Chromogranin A and its fragments in cardiovascular, immunometabolic, and cancer regulation. Ann N Y Acad Sci. 2019;1455(1):34-58. doi: 10.1111/nyas.14249.Ying W., Mahata S., Bandyopadhyay G.K. et al. Catestatin Inhibits Obesity-Induced Macrophage Infiltration and Inflammation in the Liver and Suppresses Hepatic Glucose Production, Leading to Improved Insulin Sensitivity. Diabetes. 2018 May;67(5):841-848. doi: 10.2337/db17-0788.Ying W., Mahata S., Bandyopadhyay G.K. et al. Catestatin Inhibits Obesity-Induced Macrophage Infiltration and Inflammation in the Liver and Suppresses Hepatic Glucose Production, Leading to Improved Insulin Sensitivity. Diabetes. 2018 May;67(5):841-848. doi: 10.2337/db17-0788.Dasgupta A., Bandyopadhyay G.K., Ray I. et al. Catestatin improves insulin sensitivity by attenuating endoplasmic reticulum stress: In vivo and in silico validation.Comput Struct Biotechnol J. 2020 Feb 22;18:464-481. doi: 10.1016/j.csbj.2020.02.005.Dasgupta A., Bandyopadhyay G.K., Ray I. et al. Catestatin improves insulin sensitivity by attenuating endoplasmic reticulum stress: In vivo and in silico validation.Comput Struct Biotechnol J. 2020 Feb 22;18:464-481. doi: 10.1016/j.csbj.2020.02.005.Muntjewerff E.M., Christoffersson G., Mahata S.K., van den Bogaart G. Putative regulation of macrophage-mediated inflammation by catestatin. Trends Immunol. 2022 Jan;43(1):41-50. doi: 10.1016/j.it.2021.11.002.Muntjewerff E.M., Christoffersson G., Mahata S.K., van den Bogaart G. Putative regulation of macrophage-mediated inflammation by catestatin. Trends Immunol. 2022 Jan;43(1):41-50. doi: 10.1016/j.it.2021.11.002.

The authors declare that there are no conflicts of interest present.